ERBB2 and breast carcinoma: One hundred and thirty-six patients (19.9%) were TN breast cancer identified as ER-negative, PR-negative, and HER2-negative and 529 patients (77.5%) were non-TN breast cancer indentified as HR-positive or HER2-positive.